CAD & Atherosclerosis
From the Journals
PCSK9 inhibitors for severe COVID? Pilot trial signals of benefit
“PCSK9 inhibition may represent a novel therapeutic pathway in addition to currently recommended therapeutic approaches for severe COVID-19.”
Opinion
Geriatrician advises on use of vitamin D supplementation, lecanemab, and texting for her patients
There is growing awareness of the impact of social isolation on health outcomes, particularly among older adults.
From the Journals
Evolocumab’s LDL lowering surpassed inclisiran’s in ORION-3
Results from a crossover subgroup of 92 patients in ORION-3 documented evolocumab’s greater LDL-lowering efficacy, compared with inclisiran.
From the Journals
After PCI, 1-month beats 12-month DAPT in high-risk patients
When dual was replaced by single antiplatelet therapy 1 month after PCI in Japanese patients, bleeding risk declined.
Feature
Does EPA lower CV risk? REDUCE-IT revisited
A prescription product consisting of a “highly purified” form of the omega-3 acid eicosapentaenoic acid, was heralded in 2018 as ushering in “the...
From the Journals
PPI use in type 2 diabetes links with cardiovascular events
Prospective data from almost 20,000 people with type 2 diabetes show that proton pump inhibitor use is linked with significantly more...
From the Journals
LDL cholesterol triglycerides ‘robust’ ASCVD risk marker
A large dual-method Danish population study identified high LDL triglyceride levels as a risk marker for atherosclerotic cardiovascular disease....
Feature
Recount of FOURIER data finds higher mortality with evolocumab; trialists push back
A readjudication of mortality data from the FOURIER trial by outside researchers concludes CV death was higher with evolocumab than originally...
Commentary
Five thoughts on the Damar Hamlin collapse
The cardiac arrest of Buffalo Bills footballer Damar Hamlin has led to speculation about commotio cordis and more, but this electrophysiologist...
From the Journals
STEMI times to treatment usually miss established goals
Survival and treatment times are closely linked in STEMI patients, but many still don’t get to PCI within the long-established 90- and 120-minute...
From the Journals
Heart benefits begin at well under 10,000 daily steps
The benefits of taking more daily steps accrue at well below the widely promoted threshold of 10,000 steps per day.